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ABSTRACT ARTICLE INFO
Background: The first clinical sign of chronic hepatitis C virus (HCV) infection can be one of the 
various extrahepatic manifestations. During antiviral treatment, symptoms of HCV-associated 
neuropathies usually improve, but can also worsen and lead to discontinuation of anti-HCV 
therapy. Recently, we have reported autonomic dysfunction in patients with HCV infection.
Objectives: In the present prospective study, we analyzed the changes of autonomic function 
during anti-HCV treatment.
Patients and Methods: Cardiovagal autonomic function was assessed in 22 HCV RNA-positive, 
treatment-naive patients by determining heart rate variability (HRV) and baroreflex sensitiv-
ity (BRS), at the beginning of treatment and 12, 24 and 48 weeks of antiviral therapy. interferon 
alfa-2 and ribavirin were given according to the guidelines.
Results: Both HRV and BRS time and frequency domain indices decreased after 12 weeks of ther-
apy compared to the pre-treatment values; then the mean±SD values increased significantly 
by week 24 and continued to improve by week 48 of therapy—253.0±156.1 ms before therapy vs 
111.6±81.9 at week 12, and 183.4±169.6 at week 24 vs 211.6±149.1 ms at week 48 for low-frequency 
HRV index; p<0.05 for all comparisons). These changes were independent from the presence 
of cryoglobulins and from virologic response.
Conclusions: The first rise followed by reversible autonomic dysfunction during antiviral thera-
py may be caused by the immunomodulatory actions of interferon alfa-2.
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Background 
Chronic  hepatitis  C  virus  (HCV)  infection  is  a  common 
cause of chronic liver disease and liver cirrhosis; it is the 
main cause of hepatocellular carcinoma (1). The first clinical 
sign of HCV infection can be an extrahepatic manifestation, 
which develops in more than 50% of patients during the 
course of the disease, even in the absence of hepatic symp-
toms (2, 3). Among HCV-associated extrahepatic manifesta-
tions, neurological complications are common, including 
impairment of both peripheral and central nervous system, 
e.g., peripheral motor and sensory dysfunctions, transverse 
myelopathy, cognitive impairment, fatigue, anxiety, depres-
sion, and impaired quality of life (4-6). Autonomic function 
can  be  assessed  by  reproducible  non-invasive  methods. Anti-HCV therapy and autonomic function 115 Osztovits J et al.
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Parasympathic  activity,  basal  vagal  outflow  can  be  deter-
mined by measuring various indices of heart rate variability 
(HRV), and autonomic integrative function can be estimated 
by measuring baroreflex sensitivity (BRS) indices (7, 8). De-
pressed HRV and BRS have been established as independent 
predictors of cardiovascular morbidity and mortality (9, 10). 
In addition, autonomic nerve dysfunction is well described 
in chronic alcoholic and non-alcoholic liver diseases, includ-
ing primary biliary cirrhosis and chronic hepatitis B virus 
infection. Moreover, autonomic neuropathy in chronic liver 
disease is associated with a five-fold increase in mortality 
within four years, independent from the severity of the liver 
disease (11). Autonomic dysfunction can show improvement 
as well, in patients with end-stage after liver disease after 
transplantation  (12).  In  our  previous  study,  we  have  first 
described impaired cardiovagal autonomic function in pa-
tients with chronic HCV infection (13). The response of extra-
hepatic manifestations to the current standard of antiviral 
therapy is mostly favorable (14). However, no response, wors-
ening and even the development of central and peripheral 
neurotoxicity have been reported, as well, including sensory 
and motor neuropathies, depression, irritability and anxi-
ety, leading to temporary or permanent discontinuation of 
antiviral therapy (15-18). To date, it is not known how antivi-
ral therapy affects autonomic nervous function in patients 
with chronic HCV infection.In the present study, we longitu-
dinally assessed cardiovagal autonomic function by deter-
mining HRV and BRS indices in patients with chronic HCV 
infection during antiviral therapy in parallel with markers 
of liver cell damage (serum aminotransferases), liver syn-




We followed 22 patients with chronic HCV infection dur-
ing antiviral therapy, and performed autonomic function 
and laboratory examinations one day before therapy, and 
on 12, 24 and 48 weeks of the treatment. Patients were re-
cruited from three outpatient liver clinics in Budapest, Hun-
gary, between January 2006 and December 2007. Inclusion 
criteria were 1) HCV RNA positivity; 2) no previous antiviral 
treatment; 3) no known liver disease in history other than 
chronic HCV infection; 4) no HIV or hepatitis B virus (HBV) 
co-infection; 5) no alcohol or drug abuse; 6) no histological, 
laboratory or clinical evidence of liver cirrhosis; 7) no uncon-
trolled psychiatric condition, pregnancy or lactation; 8) no 
disease that might affect autonomic nerve system, such as 
diabetes, hypertension, heart failure, ischemic heart disease, 
end-stage renal disease, stroke, Parkinson’s disease, or AIDS; 
9)  no  treatment  influencing  autonomic  nervous  system 
such  as  ß-blockers,  muscarinic  receptor  blockers;  and  10) 
having a sinus rhythm. For antiviral therapy, a white blood 
cell count <3,000/mm3, absolute neutrophil count <1,500/
mm3,  and  platelet  count  <80,000/mm3  as  well  as  uncer-
tainty  about  effective  contraception  during  therapy  were 
contraindications.  All  individuals  gave  written  informed 
consent to participate in the study. This study was approved 
by the Ethics Committee of the Semmelweis University, Bu-
dapest, Hungary.
Study design
Patients were treated with pegylated interferon (PEG-IFN) 
α-2a (40 kd, 180 μg) or PEG-IFN α-2b (12 kd, 1.5 μg/kg) subcuta-
neously once per week and ribavirin (1000 mg if wt<75 kg 
and 1200 mg if wt>75 kg) per os daily. Duration of therapy 
was  considered  individually  according  to  the  guidelines. 
Treatment responses were characterized by the results of 
HCV RNA testing. Early virologic response was defined as a 
decrease in serum HCV RNA concentration to <50 IU/mL or 
a decrease of at least 2 log units from baseline viral load 12 
weeks of therapy. SVR was defined as negativity for HCV RNA 
in serum by a PCR test at the end of the treatment and six 
months later. Autonomic function and laboratory examina-
tions were done one day before the therapy, then on 12, 24 
and 48 weeks of the treatment, depending on the individual 
duration of antiviral therapy.
Laboratory analyses
Patients underwent laboratory examination one day be-
fore autonomic function tests. Routine laboratory tests in-
cluded AST, ALT, albumin and blood glucose levels. HCV RNA 
was quantified by real-time PCR (COBAS TaqMan, Roche Di-
agnostics, Meylan, France). For the detection of mixed cryo-
globulins, blood samples were kept at 37 °C until complete 
coagulation and analyzed by standard methods.
Cardiovagal autonomic function
Blood pressure, heart rate and respiration
Radial artery pressure was monitored continuously with 
an  automated  tonometric  device  (Colin  CBM-7000;  Colin 
Corp., Komaki City, Japan) for determination of BRS indices. 
Systolic (SBP) and diastolic blood pressure (DBP), measured 
on the brachial artery by an automatic microphonic sphyg-
momanometer  built  into  the  Colin  device,  were  used  to 
calibrate the radial pressure pulse. RR intervals (RRIs) were 
measured from R-wave threshold crossings on continuously 
recorded electrocardiogram (ECG). Respiration was record-
ed with an inductive system (Respitrace System; Ambulatory 
Monitoring, Ardsley, NY, USA). To improve the reliability of 
measurements, breathing rate was paced at 0.25 Hz (19).
Baroreflex sensitivity (BRS)
The coupling between spontaneous fluctuations in heart 
rate and SBP was determined by the sequence method and 
by spectral analysis. The software used (WinCPRS program; 
Absolute Aliens Oy, Turku, Finland) detected the ECG R wave, 
computed RRI and radial artery SBP time series and identi-
fied spontaneously occurring sequences in which SBP and 
RRI  concurrently  increased  and  decreased  over  three  or 
more  consecutive  beats  (BRSseq).  The  minimal  accepted 
change was 1 mm Hg for SBP and 5 ms for RRI. Only sequenc-
es with a correlation coefficient >0.85 were considered. To 
determine spectral indices, the signals were interpolated, 
resampled and their power spectra were determined using 
fast Fourier transformation-based methods. The LFgain (LF 
[Low-Frequency]  transfer  function  gain)  was  determined, 
which expresses RRI and SBP cross-spectral magnitude in the 
frequency range of 0.05–0.15 Hz, where coherence is >0.5.Anti-HCV therapy and autonomic function 116 Osztovits J et al.
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Heart rate variability (HRV)
Time and frequency domain measurements of HRV from 
10-min recordings of RRIs were calculated using the WinCPRS 
program. Non-sinus beats were semi-automatically removed 
and corrected using interpolation of preceding beats. The 
following  parameters  were  determined:  the  standard  de-
viation of the RRI (termed NNSD), the root mean square of 
successive differences (termed RMSSD), the percentage of 
successive RRIs that differed by >50 ms (termed pNN50), 
as well as low-frequency (0.05–0.15 Hz) and high-frequency 
(0.15–0.4 Hz) power of RRI variability (termed LF and HF, re-
spectively).
Examination of cardiovagal autonomic function
Patients were studied in the early afternoon under stan-
dardized conditions, in a quiet room at a comfortable tem-
perature.  All  individuals  fasted  at  least  two  hours  before 
testing and were asked to refrain from strenuous exercise 
or drinking alcohol or caffeinated beverages for 24 hours 
before this study. Subjects were equipped with the appropri-
ate devices, and then rested in the supine position for ap-
proximately 15 minutes until baseline conditions for heart 
rate and mean blood pressure were reached. Subjects were 
then asked to synchronize their respiratory rate with a met-
ronome beating at 0.25 Hz. RR intervals and radial artery 
pressure were recorded continuously for 10 minutes to de-
termine spontaneous baroreflex indices.
Data analysis
Blood  pressure  and  ECG  recordings  were  digitized  and 
analyzed using the WinCPRS program using a sampling rate 
of 500 Hz. Data were expressed as means±SD. To assess the 
changes over time in variables of interest, repeated variance 
analysis was used with post hoc Tukey’s test. To ensure com-
pliance with the assumptions of repeated measures ANOVA 
requiring equal interval measures, two independent analy-
ses were conducted: one with values before and at 12 and 24 
weeks of treatment; and another with values before and at 
24 and 48 weeks of treatment. To preserve space, results of 
these two analyses were combined for presentation in Table 1. 
To evaluate the effect of potential determinants (age, body 
mass index [BMI], serum ALT, albumin, glucose, cryoglobu-
linemia, HCV RNA, and response to therapy) on autonomic 
(HRV and BRS) indices, we performed a multivariate analysis 
using full information maximum likelihood regression in-
cluding all selected participants and correcting for attrition. 
To correct for any violations of residual normality, robust 
standard errors were used. Serum HCV RNA level was log 
transformed to correct its highly skewed distribution. The 
null hypothesis of no relationship was rejected at p<0.05. 
Analyses were performed using Mplus version 5.2 (Muthen 
and Muthen, Los Angeles, CA, USA).
Results
Twenty-two  patients  were  eligible  and  started  antiviral 
treatment. The participants had a mean±SD age of 44.9±10.1 
(range: 26–62) years, and BMI of 26.1±5.4 (range: 19.8–40.4) kg/
m2. The mean serum HCV RNA level was 1,900,000 (range: 
5,800–10,700,000) IU/mL. Genotyping revealed HCV subtype 
1b in 21 (95%) of 22 patients, and subtype 1a in one (5%). Mixed 
cryoglobulinemia was present in eight (35%) of 22 patients 
before treatment. Study and treatment protocol was discon-
tinued in one patient in week 14 because of severe fatigue. 
One patient died of traffic accident in week 31, and another 
patient refused to participate in the study examinations in 
week 48. Of 22 patients, 15 (68%) showed an early virologi-
cal response at week 4 or 12; 11 (58%) of 19 patients achieved 
a sustained virological response (SVR). The patients’ labo-
ratory data and cardiovagal autonomic indices before and 
during antiviral treatment are shown in Table 1. The initially 
elevated AST/ALT levels were nearly normalized by week 12 of 
therapy and remained normal throughout weeks 24 and 48 
(p<0.001). Glucose or albumin levels remained unchanged 
before and during the therapy. Both heart rate variability 
sequence indices (NNSD, pNN50), frequency-domain indices 
(LF and HF), and baroreflex sensitivity indices (BRSseq, LF-
gain) were significantly decreased by week 12 (p< 0.01), and 
then increased by week 24 (p< 0.05) to reach pre-treatment 
levels by week 48 of antiviral therapy. Multivariate analyses 
did not identify a significant correlation between any of the 
anthropometric or laboratory variables studied (age, BMI, 
cryoglobulinemia,  HCV  RNA  level,  ALT,  albumin,  glucose) 
and changes of autonomic function indices during antiviral 
treatment. Response to therapy was also not associated with 
the changes of autonomic function.
Discussion
Following our previous study of autonomic dysfunction 
in patients with chronic hepatitis C (13), we investigated the 
changes of autonomic function in patients with chronic HCV 
infection during antiviral therapy. Interestingly, a significant 
decrease in autonomic function occurred by week 12 of the 
treatment to be followed by a significant improvement by 
week 24 and a return to pre-treatment values by week 48 of 
antiviral therapy. Neurological symptoms in patients with 
chronic hepatitis C usually improve during antiviral therapy. 
However, exacerbations or even the first onset of neurologi-
cal manifestations have also been observed during antiviral 
treatment. Ribavirin has no known neurological side effects; 
neither ribavirin monotherapy trials (20, 21) nor random-
ized trials comparing the combination of IFN-α and ribavi-
rin with IFN-ß monotherapy showed significant neurologi-
cal complications (22, 23). A direct neurotoxic effect of IFN-α 
in our study is unlikely because autonomic dysfunction im-
proved after three months despite the continuation of ther-
apy. However, IFN-α may induce vasculitis with or without 
cryoglobulinemia, and can increase preexisting ischemia, 
leading to purpura, skin ulcerations, arthritis or ischemic 
polyneuropathy (24, 25). None of these manifestations was 
observed in our patients with chronic HCV infection during 
antiviral therapy. Presence of cryoglobulins was not associ-
ated with the changes of autonomic function. Further mani-
festations related to neuropathies in HCV infection may be 
the HCV and IFN-α treatment-related insulin resistance (26, 
27).  Diabetic  peripheral  and  autonomic  neuropathies  are 
well known complications of persistent hyperglycemia (28). 
Similarly, impaired cardiovagal autonomic indices are early, 
subclinical signs of glucose neurotoxicity in patients with di-
abetes (29). In our study, patients with diabetes were exclud-
ed and fasting glucose levels did not change during antiviral 
therapy. Therefore, an impaired carbohydrate metabolism 
does not underlie the changes of autonomic dysfunction in Anti-HCV therapy and autonomic function 117 Osztovits J et al.
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